**e Figure 1.** Kaplan-Meier curve of time to death from hospital admission through 12-month follow-up among patients with (N=220) or without (N=231) neurological complications during hospitalization. Patients with 6-month and/or 12-month follow-up interviews were included (total N=451).

Red= Neurological Event
Blue=No neurological event

Log rank P=0.379

eTable 1. Functional, cognitive and patient-reported outcome metrics at 6-months and 12-months post COVID-19 symptom onset in *all* patients who completed interviews at either time point. Note that only N=174 patients completed both 6- and 12-month interviews. N=208 patients completed only 6-month follow-up and N=68 patients completed only the 12-month interview.

Outcome Measure	Baseline	6-month N=382	12-month N=242
mRS median (IQR)	0 (0-1)	3 (0-6)	2 (0-6)
mRS>0, N (%)	99/297 (33%)	310/380 (82%) 137/198 (69%)*	176/235 (75%) 90/138 (65%)*
Barthel median (IQR), Barthel <100, N (%)	-- --	100 (80-100) 134/304 (44%)	100 (85-100) 86/236 (36%)
tMoCA median (IQR)	--	18 (15-19)	19 (15-20)
tMOCA ≤18, N (%) tMOCA (≤18) excluding h/o dementia, N (%)	--	134/215 (62%) 122/201 (61%)	85/170 (50%) 80/161 (50%)
Neuro-QoL Anxiety T-score, median (IQR)	--	48 (42-54)	47 (36-53)
Anxiety T-score>60, N (%)	--	21/280 (8%)	16/225 (7%)
Neuro-QoL Depression T-score, median (IQR) Depression T-score>60, N (%)	-- --	45 (37-51) 8/279 (3%)	43 (37-50) 9/225 (4%)
Neuro-QoL Fatigue T-score, median (IQR) Fatigue T-score>60, N (%)	-- --	45 (40-53) 14/272 (5%)	45 (38-53) 20/223 (9%)
Neuro-QoL Sleep T-Score, median (IQR) Sleep T-score>60, N (%)	-- --	46 (39-53) 27/278 (10%)	46 (36-53) 22/221 (10%)
Total patients with at least one abnormal metric	--	337/369 (91%) 160/189 (85%)*	197/227 (87%) 107/130 (82%)*

*Excluding pts with mRS>0 baseline. This percentage indicates the patients with new functional disability after COVID-19 hospitalization
mRS=modified Rankin Scale; t-MoCA=telephone Montreal Cognitive Assessment; IQR=interquartile range; QoL=quality of life